122 related articles for article (PubMed ID: 22607122)
1. Discovery of highly potent human deoxyuridine triphosphatase inhibitors based on the conformation restriction strategy.
Miyahara S; Miyakoshi H; Yokogawa T; Chong KT; Taguchi J; Muto T; Endoh K; Yano W; Wakasa T; Ueno H; Takao Y; Fujioka A; Hashimoto A; Itou K; Yamamura K; Nomura M; Nagasawa H; Shuto S; Fukuoka M
J Med Chem; 2012 Jun; 55(11):5483-96. PubMed ID: 22607122
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a novel class of potent human deoxyuridine triphosphatase inhibitors remarkably enhancing the antitumor activity of thymidylate synthase inhibitors.
Miyahara S; Miyakoshi H; Yokogawa T; Chong KT; Taguchi J; Muto T; Endoh K; Yano W; Wakasa T; Ueno H; Takao Y; Fujioka A; Hashimoto A; Itou K; Yamamura K; Nomura M; Nagasawa H; Shuto S; Fukuoka M
J Med Chem; 2012 Apr; 55(7):2970-80. PubMed ID: 22339362
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and discovery of N-carbonylpyrrolidine- or N-sulfonylpyrrolidine-containing uracil derivatives as potent human deoxyuridine triphosphatase inhibitors.
Miyakoshi H; Miyahara S; Yokogawa T; Chong KT; Taguchi J; Endoh K; Yano W; Wakasa T; Ueno H; Takao Y; Nomura M; Shuto S; Nagasawa H; Fukuoka M
J Med Chem; 2012 Apr; 55(7):2960-9. PubMed ID: 22404301
[TBL] [Abstract][Full Text] [Related]
4. 1,2,3-Triazole-containing uracil derivatives with excellent pharmacokinetics as a novel class of potent human deoxyuridine triphosphatase inhibitors.
Miyakoshi H; Miyahara S; Yokogawa T; Endoh K; Muto T; Yano W; Wakasa T; Ueno H; Chong KT; Taguchi J; Nomura M; Takao Y; Fujioka A; Hashimoto A; Itou K; Yamamura K; Shuto S; Nagasawa H; Fukuoka M
J Med Chem; 2012 Jul; 55(14):6427-37. PubMed ID: 22715973
[TBL] [Abstract][Full Text] [Related]
5. Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase.
Nguyen C; Ruda GF; Schipani A; Kasinathan G; Leal I; Musso-Buendia A; Kaiser M; Brun R; Ruiz-Pérez LM; Sahlberg BL; Johansson NG; Gonzalez-Pacanowska D; Gilbert IH
J Med Chem; 2006 Jul; 49(14):4183-95. PubMed ID: 16821778
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor.
Moffat D; Patel S; Day F; Belfield A; Donald A; Rowlands M; Wibawa J; Brotherton D; Stimson L; Clark V; Owen J; Bawden L; Box G; Bone E; Mortenson P; Hardcastle A; van Meurs S; Eccles S; Raynaud F; Aherne W
J Med Chem; 2010 Dec; 53(24):8663-78. PubMed ID: 21080647
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
9. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo.
Wendt MD; Shen W; Kunzer A; McClellan WJ; Bruncko M; Oost TK; Ding H; Joseph MK; Zhang H; Nimmer PM; Ng SC; Shoemaker AR; Petros AM; Oleksijew A; Marsh K; Bauch J; Oltersdorf T; Belli BA; Martineau D; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2006 Feb; 49(3):1165-81. PubMed ID: 16451081
[TBL] [Abstract][Full Text] [Related]
10. Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor.
Brasca MG; Amboldi N; Ballinari D; Cameron A; Casale E; Cervi G; Colombo M; Colotta F; Croci V; D'Alessio R; Fiorentini F; Isacchi A; Mercurio C; Moretti W; Panzeri A; Pastori W; Pevarello P; Quartieri F; Roletto F; Traquandi G; Vianello P; Vulpetti A; Ciomei M
J Med Chem; 2009 Aug; 52(16):5152-63. PubMed ID: 19603809
[TBL] [Abstract][Full Text] [Related]
11. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and antitumor effect in vitro and in vivo of substituted 1,3-dihydroindole-2-ones.
Christensen MK; Erichsen KD; Trojel-Hansen C; Tjørnelund J; Nielsen SJ; Frydenvang K; Johansen TN; Nielsen B; Sehested M; Jensen PB; Ikaunieks M; Zaichenko A; Loza E; Kalvinsh I; Björkling F
J Med Chem; 2010 Oct; 53(19):7140-5. PubMed ID: 20845961
[TBL] [Abstract][Full Text] [Related]
13. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
Cohen F; Bergeron P; Blackwood E; Bowman KK; Chen H; Dipasquale AG; Epler JA; Koehler MF; Lau K; Lewis C; Liu L; Ly CQ; Malek S; Nonomiya J; Ortwine DF; Pei Z; Robarge KD; Sideris S; Trinh L; Truong T; Wu J; Zhao X; Lyssikatos JP
J Med Chem; 2011 May; 54(9):3426-35. PubMed ID: 21495671
[TBL] [Abstract][Full Text] [Related]
14. Structure-activity relationships of C-17 cyano-substituted estratrienes as anticancer agents.
Leese MP; Jourdan FL; Gaukroger K; Mahon MF; Newman SP; Foster PA; Stengel C; Regis-Lydi S; Ferrandis E; Di Fiore A; De Simone G; Supuran CT; Purohit A; Reed MJ; Potter BV
J Med Chem; 2008 Mar; 51(5):1295-308. PubMed ID: 18260615
[TBL] [Abstract][Full Text] [Related]
15. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
[TBL] [Abstract][Full Text] [Related]
17. Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.
Harmange JC; Weiss MM; Germain J; Polverino AJ; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; DiPietro L; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Martin MW; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Wang L; White RD; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1649-67. PubMed ID: 18324761
[TBL] [Abstract][Full Text] [Related]
18. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: discovery of novel orally active inhibitors of human thymidine phosphorylase.
Yano S; Kazuno H; Suzuki N; Emura T; Wierzba K; Yamashita J; Tada Y; Yamada Y; Fukushima M; Asao T
Bioorg Med Chem; 2004 Jul; 12(13):3431-41. PubMed ID: 15186829
[TBL] [Abstract][Full Text] [Related]
20. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer.
Brough PA; Aherne W; Barril X; Borgognoni J; Boxall K; Cansfield JE; Cheung KM; Collins I; Davies NG; Drysdale MJ; Dymock B; Eccles SA; Finch H; Fink A; Hayes A; Howes R; Hubbard RE; James K; Jordan AM; Lockie A; Martins V; Massey A; Matthews TP; McDonald E; Northfield CJ; Pearl LH; Prodromou C; Ray S; Raynaud FI; Roughley SD; Sharp SY; Surgenor A; Walmsley DL; Webb P; Wood M; Workman P; Wright L
J Med Chem; 2008 Jan; 51(2):196-218. PubMed ID: 18020435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
